

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Date of report: January 24, 2022

Commission File Number: 001-38844

**GENFIT S.A.**

(Translation of registrant's name into English)

Parc Eurasanté  
885, avenue Eugène Avinée  
59120 Loos, France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

EXHIBIT LIST

<u>Exhibit</u>	<u>Description</u>
<a href="#">99.1</a>	<a href="#">Press Release dated January 24, 2022.</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**GENFIT S.A.**

Date: January 24, 2022

By: /s/ Pascal PRIGENT  
Name: Pascal PRIGENT  
Title: Chief Executive Officer



## GENFIT: 2022 Financial Calendar

**Lille, France; Cambridge, MA; January 24, 2022** - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its provisional financial calendar for 2022.

February 28, 2022:	Publication of revenue and cash position at December 31, 2021
April 07, 2022:	Publication of Full Year 2021 financial statements  <i>The 2020 Universal Registration Document and Annual Financial Report (included in the Universal Registration Document), as well as the Annual Report on Form 20-F will be made public by the end of April 2022</i>
May 11, 2022:	Publication of revenue and cash position at March 31, 2022
May 25, 2022:	Annual Shareholders Meeting
September 28, 2022:	Publication of the Half Year 2022 financial statements
November 10, 2022:	Publication of revenue and cash position at September 30, 2022

This calendar is subject to change.

### ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.

Its R&D is focused on three franchises: cholestatic diseases, Acute on Chronic Liver Failure (ACLF) and NASH diagnostics. In its cholestatic diseases franchise, ELATIVE™, a Phase 3 global trial evaluating elafibranor<sup>1</sup> in patients with Primary Biliary Cholangitis (PBC) is well underway

<sup>1</sup> Elafibranor and GNS561 are investigational compounds that have not been reviewed nor been approved by a regulatory authority



---

## PRESS RELEASE

following a successful Phase 2 clinical trial. Topline data is expected to be announced in early 2023. In 2021, GENFIT signed an exclusive licensing agreement with IPSEN<sup>2</sup> to develop, manufacture and commercialize elafibranor in PBC and other indications. GENFIT is also developing GNS561<sup>1</sup> in cholangiocarcinoma following the acquisition of exclusive rights in this indication from Genoscience Pharma in 2021<sup>3</sup>. In ACLF, a Phase 1 clinical program with nitazoxanide has been initiated with data expected as early as the third quarter 2022. As part of its diagnostic solutions franchise, the Company entered into an agreement with Labcorp in 2021 to commercialize NASHnext®, powered by GENFIT's proprietary diagnostic technology NIS4® in identifying at-risk NASH.

GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext's regulated market in Paris (Nasdaq and Euronext: GNFT) . In 2021, IPSEN became one of GENFIT's largest shareholders and holds 8% of the company's share capital. [www.genfit.com](http://www.genfit.com)

### FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding GENFIT's research and development programs and planned release of financial information. The use of certain words, including "consider", "contemplate", "think", "aim", "expect", "understand", "should", "aspire", "estimate", "believe", "wish", "may", "could", "allow", "seek", "encourage" or "have confidence" or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company's management, these forward- looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Company's continued ability to raise capital to fund its development, as well as those risks and

<sup>2</sup> With the exception of China, Hong Kong, Taiwan, and Macau where Terns Pharmaceuticals holds the exclusive license to develop and commercialize elafibranor

<sup>3</sup> Agreement includes commercialization and development in the United States, Canada and Europe, including the United Kingdom and Switzerland



---

## PRESS RELEASE

uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Main Risks and Uncertainties" of the Company's 2019 Universal Registration Document filed with the AMF on 27 May 2020 under n° D.20-0503 and in Section 2 "Risk Factors" of the Company's Amendment to the Universal Registration Document filed with the AMF on 22 December 2020 under n° D.20-0503-A01, which are available on the Company's website ([www.genfit.com](http://www.genfit.com)) and on the website of the AMF ([www.amf-france.org](http://www.amf-france.org)) and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC") including the Company's 2019 Annual Report on Form 20-F filed with the SEC on May 27, 2020. In addition, even if the Company's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

### CONTACT

**GENFIT | Investors**

Tel: +33 3 2016 4000 | [investors@genfit.com](mailto:investors@genfit.com)

**PRESS RELATIONS | Media**

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | [stephanie.boyer@genfit.com](mailto:stephanie.boyer@genfit.com)